In the 1st phase I study, 26 individuals with incurable advanced and/or metastatic solid nine patients experienced steady disease; seven of 27 in the next study achieved steady disease. Access has signed an contract to conduct a medical research in this indication at MD Anderson, and the analysis is likely to start enrolling in August 2010.. Access Pharmaceuticals initiates Stage I/II dosage escalating study for Thiarabine Access Pharmaceuticals, Inc. , today announced it provides initiated a Phase I/II dose-escalating research of its proprietary, anti-cancer medication, Thiarabine, a nucleoside analog for individuals with hematologic malignancies . The planned program is being led by Hagop Kantarjian, M.D., Chair of the Division of Leukemia at The University of Texas MD Anderson Tumor Center in Houston, Texas.NEISS-CADES can be a joint work of the CDC, the United States Consumer Product Safety Commission, and the meals and Drug Administration. Previous studies have suggested that half of the estimated 100 million antibiotic prescriptions created locally setting each year for respiratory tract infections could be unnecessary. For circumstances where antibiotics have questionable advantage, such as many mild top respiratory system infections, weighing the advantages of antibiotics with the dangers of a serious adverse event will end up being especially important, said Budnitz.